NOVEL IMMUNOTHERAPIES IN LYMPHOMA
With
Dr Sean Harrop
Clinical Haematology Fellow
Peter MacCallum Cancer Centre,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | May 2025
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
He has research interests in novel immunotherapies in lymphoma, mechanisms that lead to immunotherapy resistance and the genetic mechanisms underlying the tumour microenvironment.
He has published in peer-reviewed journals, co-authored textbook chapters and presented at international conferences on clinical and translational research in lymphoma.
Dr Harrop’s upcoming PhD is funded by the Leukaemia Foundation, Haematology Society of Australia and New Zealand (HSANZ) and the Peter MacCallum Cancer Centre.
Source: Supplied and adapted
-
Relationship between mental illness and mental wellbeing
Since 2015, Dr Matthew Iasiello has been working on the development and dissemination of mental wellbeing interventions across the Australian community at the South Australian Health and Medical Research Institute (SAHMRI). His PhD research was designed specifically to strengthen the translational work conducted by SAHMRI, and to solve problems that represented gaps in the literature that were arising when delivering mental wellbeing interventions into the community. The impact and relevance of Dr Iasiello’s work has been demonstrated with invited presentations at international academic conferences, and multiple media stories with significant online engagements.
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
